

Types and structure of complications, and causes of mortality with different combinations of immunosuppressants in patients of undergoing organ transplantation

Jamalbek Ashimov, Janybek Gaibylidaev

SRI of Heart Surgery and Organ Transplantation, Bishkek, Kyrgyzstan

Abstract

We aimed to retrospectively analyze morbidity and mortality in recipients of kidney and liver transplant receiving immunosuppressive therapy (tacrolimus and cyclosporine with mycophenolate mofetil and mycophenolic acid). Overall, 228 patients who underwent kidney and liver transplantation were included in the study. The overall graft survival of patients who underwent kidney and liver transplantation from 1999 to 2017 was 84.2%. Combinations including cyclosporine, were associated with high rate of complications acute rejection, CMV and candida infections as compared to tacrolimus. The most unfavorable in terms of mortality was combination of cyclosporine - mycophenolate mofetil.

Key words: kidney transplantation, liver transplantation, immunosuppression therapy, survival

One of the important problems of modern transplantology is the creation of combination of immunosuppressants having the lowest possible toxic effects on the body of the recipient. The most frequent variety of infectious complications, sometimes reaching to sepsis and lethal outcome in patients receiving immunosuppressants (1-10).

Many modern immunosuppressants effectively suppress the immune system of recipients after transplantation of vital organs, but also affect other organs, causing hypo- and aplasia of the bone marrow with the progress of agranulocytosis (7-10).

In remote period in patients receiving immunosuppressants, carcinogenic and teratogenic side effects may develop (7-11).

All these factors force to seek new combinations of immunosuppressants in dosages that provide sufficient suppressive effect, avoiding toxic effects. The most common cause of reduced graft function and occasionally recipients' mortality during the first year after transplantation is infection, especially cytomegalovirus infection (CMV). Cytomegalovirus infection may be primary and associated with the reactivation of the virus in a recipient with positive results of serological tests as a consequence of immunosuppressive therapy. Approximately 90% of patients are able to cope with infection, and they do not have any symptoms, but in 5-10% of cases, it leads to death (7-10).

There are studies on outcomes and side effects of immunosuppressive therapy in kidney and liver transplant patients with new combinations of immunosuppressant therapies (11-16), however short-term and long-term effects of combinations of immunosuppressive therapy (tacrolimus and cyclosporine with mycophenolate mofetil and mycophenolic acid) on morbidity and mortality after kidney and liver transplantation need further investigation.

We aimed to retrospectively analyze and present preliminary results on the effects of immunosuppressive therapy (tacrolimus and cyclosporine with mycophenolate mofetil and mycophenolic acid) on morbidity and mortality after kidney and liver transplantation in cohort of patients being followed-up at our institution.

We retrospectively analyzed records of 228 patients who underwent organ (kidney - 178 and liver - 50) transplantation between 1999 and 2017, received immunosuppression therapy and have been followed up in our clinic.

The following data were collected: type of immunosuppressive therapy, proportion of acute rejection, overdose, cytomegalovirus and candidiasis infections, and mortality, countries where patients underwent kidney transplantation and rate of return to hemodialysis. Survival analysis was based on 1-5-10-year follow-up data.

Address for Correspondence: Janybek Gaibylidaev,

SRI of Heart Surgery and Organ Transplantation, Bishkek, Kyrgyzstan, E-mail: janybek_86@mail.ru

Received: 23.08.2017 Accepted: 10.09.2017

Copyright© 2017 Heart Vessels and Transplantation

Statistical analysis was performed using Chi-square test to compare proportions.

Table 1 reflects a different combination of immunosuppressants that were received by patients after organ transplantation. Of these, 51.3% received the combination of tacrolimus - mycophenolate mofetil, 28% - tacrolimus - mycophenolic acid, 15% - cyclosporine - mycophenolate mofetil, and 6% - cyclosporine - mycophenolic acid.

The table 2 shows the causes of complications in different combinations of immunosuppressants. Complications were common in combination of cyclosporine and mycophenolate mofetil, and mortality was 14.3%. Analysis results are also clearly shown in the Figure 1.

Figure 2 illustrates the causes of complications in various combinations of immunosuppressants. Acute rejection




Figure 1. Types and rate of immunosuppressive therapy complications

C-MA - cyclosporine A-mycophenolic acid, C-MM - cyclosporine A-mycophenolate mofetil, CMV - cytomegalovirus, T-MA - tacrolimus-mycophenolate mofetil, T-MM - tacrolimus-mycophenolic acid

Table 1. Types of immunosuppressive therapy

| Types of immunosuppressive therapy | % |
|--------------------------------------|------|
| Tacrolimus - Mycophenolate mofetil | 51.3 |
| Tacrolimus - Mycophenolic acid | 28 |
| Cyclosporine - Mycophenolate mofetil | 15 |
| Cyclosporine - Mycophenolic acid | 6 |

Table 2. Analysis of complications of different combinations of immunosuppression

| Immunosuppressant's induction | Number of patients, n (%) | Acute rejection, n (%) | Overdose, n (%) | Cytomegalovirus infection, n (%) | Candidiasis, n (%) | Mortality, n (%) |
|---------------------------------------|---------------------------|------------------------|-----------------|----------------------------------|--------------------|------------------|
| Tacrolimus, Mycophenolate mofetil | 117 (51.3) | 5 (4.0) | 5 (4.0) | 9 (7.7) | 3 (1.3) | 5 (2.2) |
| Cyclosporine A, Mycophenolate mofetil | 35 (15) | 3 (8.5) | 3 (8.5) | 6 (17.1) | 2 (5.7) | 5 (14.3) |
| Tacrolimus, Mycophenolic acid | 62 (28.0) | 3 (4.8) | 2 (3.2) | 7 (11.3) | 5 (8.1) | 1 (1.6) |
| Cyclosporine A, Mycophenolic acid | 14 (6.0) | 2 (14.2) | 1 (7.1) | 1 (7.1) | - | - |
| Total | 228 | 14(6.1) | 11(4.8) | 23 (10.1) | 10 (4.4) | 11 (4.8) |

was often observed in combination with tacrolimus and mycophenolate mofetil at 4.0%. Despite the strict control of the dosage, overdose was observed and amounted to 4.0% in combination of tacrolimus and mycophenolate mofetil. CMV infection was found in all the combinations, but the combination of cyclosporine and mycophenolate mofetil amounted to 17.1%, being asymptomatic in 8% of patients, and in 5% patients was accompanied with deterioration of graft function and mortality. Candida infection was identified with 15% of patients. Mortality and candida infection were not observed in combination of cyclosporine and mycophenolic acid, however acute rejection was characteristic for this combination. Cyclosporine and mycophenolate mofetil caused high rate of complications and mortality (14.3%).

Analysis of causes of mortality (Fig. 2) revealed the highest percentage was accounted for chronic rejection, followed by acute rejection, CMV infection and sepsis, hepatic failure and cancer.

After transplantation in case of rejection after the loss of graft function (Fig. 3), 15 (7.02%) patients returned to hemodialysis. There were 105 transplantations in the Republic of Turkey, 4 patients returned to hemodialysis, 30 transplantations in the Pakistan, 4 patients returned to hemodialysis, 26 transplantations in the Kyrgyz Republic, 2 patients returned to hemodialysis.

There were identified cases of acute and chronic rejection of different degrees at early stage, that was successfully managed




Figure 2. Causes of mortality in patients on immunosuppressive therapy after organ transplantation

CMV - cytomegalovirus infection

with drugs in 17 (11.2%) of patients after the transplantation of kidney.

The overall graft survival in all patients from 1999 to 2017 was 84.2% (Fig. 4 and Table 3.). Among patients who underwent kidney transplantation and returned to hemodialysis, 4.8% - after transplantectomy and 2.2% without removal of graft,




Figure 3. Absolute number of patients returned to hemodialysis program by country




Figure 4. Survival of grafts and patients

Table 3. Mortality and survival analysis of grafts and patients (1999-2017)

| | |
|--|----------|
| Overall survival of grafts, % | 84.2 |
| Overall survival of patients, % | 91.2 |
| Return to hemodialysis, n(%) | 16 (7.0) |
| With kidney removal (transplantectomy), % | 4.8 |
| Without kidney removal, % | 2.2 |
| 1-year grafts' survival, % | 94.7 |
| 1-year patients' survival, % | 95.6 |
| 5-year grafts' survival, % | 74.2 |
| 5-year patients' survival, % | 92.2 |
| 10-year grafts' survival, % | 52.4 |
| 10-year patients' survival, % | 87 |
| Overall mortality, n(%) | 20 (8.7) |
| Mortality after liver transplantation, n(%) | 3 (21.4) |
| Mortality after kidney transplantation, n(%) | 17 (7.9) |

mortality rate for kidney transplantation was 7.9%. Mortality rate after liver transplantation was - 21.4%.

Our study has limitations as being descriptive in design and includes relative small number of patients.

In conclusion, the overall graft survival of patients who underwent kidney and liver transplantation from 1999 to 2017 was 84.2%. Combinations including cyclosporine, were associated with high rate of complications acute rejection, CMV and candida infections as compared to tacrolimus. The most unfavorable in terms of mortality was combination of cyclosporine - mycophenolate mofetil.

Peer-review: Internal

Conflict of interest: None to declare

Authorship: J.A. and J.G. equally contributed to the preparation of brief report

Acknowledgement and funding: None to declare.

Informed consent for procedures and treatment was obtained from all patients as a part of center policy (retrospective study)

References

- Danovitch GM. Handbook of Kidney Transplantation. 5th ed. Philadelphia (PA): Lippincott Williams&Wilkins; 2009: 471.
- Moisiuk IG, Stoliarevich ES, Tomilina NA. Disease of kidney transplant. In: Mukhin NA, ed. Nephrology: national manual. Moscow: GEOTAR-Media; 2009: 588.
- Sigitova ON. Chronic renal disease and chronic renal failure: current approaches to terms, classification and diagnosis. The Bulletin of Contemporary Clinical Medicine 2008; 1; 83-8.
- Kalble T, Alcaraz A, Budde K, Humke U, Karam G, Lucan M, et al. Guidelines on renal transplantation. European Association of Urology, 2010. Available at: URL: <http://uroweb.org/wp-content/uploads/EAU-Guidelines-Renal-Transplantation-2010.pdf> (Accessed 26.08.2017).
- Yagudina RI, Kulikov AL, Nguen T. The definition of "threshold willingness-to-pay»: In Russia, In Europe Countries and in CIS countries. Modern pharmacoconomics and pharmacoepidemiology 2011; 4: 7-13.
- Kalble T, Lucan M, Nicita G, Sells R, Burgos Revilla FJ, Wiesel M; European Association of Urology. EAU guidelines on renal transplantation. Eur Urol 2005; 47: 156-66.
- Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of cadaveric transplant. N Engl J Med 1999; 341: 1725-30.
- Morris PJ, Knechtle SJ. Kidney transplantation: principles and practice. 6th ed. Philadelphia (PA): Elsevier Saunders; 2008: 761.
- Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9(Suppl 3): 1-155.
- Hardinger KL, Brennan DC, Klein CL. Selection of induction therapy in kidney transplantation Transpl Int 2012; 26: 662-72.
- Perez-Aytes A, Marin-Reina P, Boso V, Ledo A, Carey JC, Vento M. Mycophenolate mofetil embryopathy: A newly recognized teratogenic syndrome. Eur J Med Genet 2017; 60: 16-21.
- Maripuri S, Kasiske BL. The role of mycophenolate mofetil in kidney transplantation revisited. Transplant Rev (Orlando) 2014; 28: 26-31.

13. Rutkowski B, Bzoma B, Debska-Slizien A, Chamienia A. Generic formulation of mycophenolate mofetil (Myfenax) in de novo renal transplant recipients: results of 12-month observation. *Transplant Proc* 2014; 46: 2683-8.
14. Gonzalez-Martínez F, Orihuela S, Orihuela N, Manzo L, Nuñez N, Nin M. Descriptive retrospective comparative study between two brands of mycophenolate mofetil used in Uruguay: innovator versus generic (Suprimun). *Transplant Proc* 2014; 46: 2996-9.
15. Kim H, Yi NJ, Lee J, Kim J, Moon MR, Jeong J, et al. Safety of reduced dose of mycophenolate mofetil combined with tacrolimus in living-donor liver transplantation. *Clin Mol Hepatol* 2014; 20: 291-9.
16. Huang HF, Yao X, Chen Y, Xie WQ, Shen-Tu JZ, Chen JH. Cyclosporine A and tacrolimus combined with enteric-coated mycophenolate sodium influence the plasma mycophenolic acid concentration - a randomised controlled trial in Chinese live related donor kidney transplant recipients. *Int J Clin Pract Suppl* 2014; 181: 4-9.